These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 15693849)
1. Her2 genotype and breast cancer progression in Korean women. An HJ; Kim NK; Oh D; Kim SH; Park MJ; Jung MY; Kang H; Kim SG; Lee KP; Lee KS Pathol Int; 2005 Feb; 55(2):48-52. PubMed ID: 15693849 [TBL] [Abstract][Full Text] [Related]
2. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer. Naidu R; Har YC; Taib NA J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142 [TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Naidu R; Yip CH; Taib NA Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245 [TBL] [Abstract][Full Text] [Related]
4. HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis. Tao W; Wang C; Han R; Jiang H Breast Cancer Res Treat; 2009 Mar; 114(2):371-6. PubMed ID: 18438707 [TBL] [Abstract][Full Text] [Related]
5. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Park K; Han S; Kim HJ; Kim J; Shin E Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686 [TBL] [Abstract][Full Text] [Related]
6. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women. Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674 [TBL] [Abstract][Full Text] [Related]
7. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. Lee SC; Hou MF; Hsieh PC; Wu SH; Hou LA; Ma H; Tsai SM; Tsai LY Clin Biochem; 2008 Feb; 41(3):121-5. PubMed ID: 18062925 [TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Akisik E; Dalay N Exp Mol Pathol; 2004 Jun; 76(3):260-3. PubMed ID: 15126109 [TBL] [Abstract][Full Text] [Related]
9. HER-2/neu Ile655Val polymorphism and the risk of breast cancer. Siddig A; Mohamed AO; Kamal H; Awad S; Hassan AH; Zilahi E; Al-Haj M; Bernsen R; Adem A Ann N Y Acad Sci; 2008 Sep; 1138():84-94. PubMed ID: 18837888 [TBL] [Abstract][Full Text] [Related]
10. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Tommiska J; Eerola H; Heinonen M; Salonen L; Kaare M; Tallila J; Ristimäki A; von Smitten K; Aittomäki K; Heikkilä P; Blomqvist C; Nevanlinna H Clin Cancer Res; 2005 Jul; 11(14):5098-103. PubMed ID: 16033823 [TBL] [Abstract][Full Text] [Related]
11. A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women. Zubor P; Lasabova Z; Hatok J; Stanclova A; Danko J Oncol Rep; 2007 Jul; 18(1):211-7. PubMed ID: 17549370 [TBL] [Abstract][Full Text] [Related]
12. Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Kamali-Sarvestani E; Talei AR; Merat A Cancer Lett; 2004 Nov; 215(1):83-7. PubMed ID: 15374636 [TBL] [Abstract][Full Text] [Related]
13. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Zúbor P; Vojvodová A; Danko J; Kajo K; Szunyogh N; Lasabová Z; Biringer K; Visnovský J; Dókus K; Galajda P; Plank L Neoplasma; 2006; 53(1):49-55. PubMed ID: 16416013 [TBL] [Abstract][Full Text] [Related]
14. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event. Hanna W; Nofech-Mozes S; Kahn HJ Breast J; 2007; 13(2):122-9. PubMed ID: 17319852 [TBL] [Abstract][Full Text] [Related]
15. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Puputti M; Sihto H; Isola J; Butzow R; Joensuu H; Nupponen NN Cancer Genet Cytogenet; 2006 May; 167(1):32-8. PubMed ID: 16682283 [TBL] [Abstract][Full Text] [Related]
16. The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer. van Gils CH; Onland-Moret NC; Roest M; van Noord PA; Peeters PH Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1194-9. PubMed ID: 14652280 [TBL] [Abstract][Full Text] [Related]
17. Risk of genome-wide association study newly identified genetic variants for breast cancer in Chinese women of Heilongjiang Province. Jiang Y; Han J; Liu J; Zhang G; Wang L; Liu F; Zhang X; Zhao Y; Pang D Breast Cancer Res Treat; 2011 Jul; 128(1):251-7. PubMed ID: 21197568 [TBL] [Abstract][Full Text] [Related]
18. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. Short SM; Yoder BJ; Tarr SM; Prescott NL; Laniauskas S; Coleman KA; Downs-Kelly E; Pettay JD; Choueiri TK; Crowe JP; Tubbs RR; Budd TG; Hicks DG Breast J; 2007; 13(2):130-9. PubMed ID: 17319853 [TBL] [Abstract][Full Text] [Related]
19. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Frank B; Hemminki K; Wirtenberger M; Bermejo JL; Bugert P; Klaes R; Schmutzler RK; Wappenschmidt B; Bartram CR; Burwinkel B Carcinogenesis; 2005 Mar; 26(3):643-7. PubMed ID: 15550452 [TBL] [Abstract][Full Text] [Related]
20. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]